3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Sarcoma
1
Lymphoid
1
Genitourinary
1
Conditions
Sarcoma
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Magnetic Resonance Spectroscopy
10
X-Rays
7
Specimen Handling
7
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Biopsy
6
ulixertinib
3
palbociclib
3
larotrectinib
3
erdafitinib
3
Temozolomide
3
tipifarnib
2
tazemetostat
2
selpercatinib
2
olaparib
2
ivosidenib
2
ensartinib
2
Vemurafenib
2
Thalidomide
2
Paclitaxel
2
Nivolumab
2
LY3023414
2
Gemcitabine
2
Erlotinib Hydrochloride
2
Cisplatin
2
Carboplatin
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
CLR1404
×
Genitourinary
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled